# LASER301 (NCT04248829)

> Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04248829
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Yuhan Corporation
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Lazertinib 240 mg/160 mg; Gefitinib 250 mg; Lazertinib-matching placebo 240 mg/160 mg; Gefitinib-matching placebo 250 mg
- Enrollment: 393
- Primary outcome: Progression-Free Survival (PFS) According to RECIST v1.1 by Investigator Assessment

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 9
- Podcasts: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=laser301-nct04248829

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04248829", "email": "<work email>"}; the inbox owner confirms by the emailed link.